CoChat
Sign Up
Cited by 70Asthma and respiratory diseasesInflammatory mediators and NSAID effectsEicosanoids and Hypertension Pharmacology

The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.

Lipid mediators and allergic diseases

Open access
Fanning, Laura B., Boyce, Joshua A.·2013·Annals of Allergy, Asthma & Immunology
DOI 10.1016/j.anai.2013.06.031PMC PMC4088989
Open this paper in CoChat — free account

Abstract

Objective To review the basic science and translational relevance of lipid mediators in the pathobiology of allergic diseases.Data sources PubMed was searched for articles using the key terms lipid mediator, prostaglandin, prostanoid, leukotriene, thromboxane, asthma, and allergic inflammation.Study selections Articles were selected based on their relevance to the goals of this review. Articles with a particular focus on clinical and translational aspects of basic science discoveries were emphasized.Results Lipid mediators are bioactive molecules generated from cell membrane phospholipids. They play important roles in many disease states, particularly in inflammatory and immune responses. Lipid mediators and their receptors are potentially useful as diagnostic markers of disease and therapeutic targets.Conclusions Several useful therapeutic agents have been developed based on a growing understanding of the lipid mediator pathways in allergic disease, notably the cysteinyl leukotriene receptor type 1 antagonists and the 5-lipoxygenase inhibitor, zileuton. Additional receptor agonists and antagonists relevant to these pathways are in development, and it is likely that future pharmacologic treatments for allergic disease will become available as our understanding of these molecules continues to evolve.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.anai.2013.06.031

Cites

110 of 110 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Leukotriene C4 is a lipid mediator that is released during MCA and undergoes metabolism into leukotriene D4, which is then converted to leukotriene E4.

    “In addition, leukotriene C 4 is a lipid mediator that is released during MCA and undergoes metabolism into leukotriene D4, which is then converted to leukotriene E4.”

    From Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review (2021) · cites this paper as [67]

    The ‘Overview of the 5-LO Pathway’ states that LTC4 is a cysteinyl leukotriene exported from the cell and converted to LTD4, then LTE4. It does not specify that LTC4 is released during mast cell activation (MCA), so that part of the claim is not supported by our copy. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Metadata

Authors
Fanning, L. B., & Boyce, J. A.
Affiliations
Brigham and Women's Hospital (US)
Corresponding author
Fanning, Laura B.
ORCID
Boyce, Joshua A.
Venue
Annals of Allergy, Asthma & Immunology
Publisher
Elsevier BV
Published
2013-09
Volume
111
Issue
3
Pages
155-162
ISSN
1081-1206 (ISSN-L)
DOI
10.1016/j.anai.2013.06.031
PMC
PMC4088989
OpenAlex
W1967253615
Cited by
70
References
110
Citations by year
2026: 4 · 2025: 2 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 11 · 2020: 5 · 2019: 5 · 2018: 7 · 2017: 6 · 2016: 7 · 2015: 9 · 2014: 8
FWCI
0.88
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of Allergy Asthma & Immunology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • U.S. Public Health Service (53202, A100306)
  • National Institute of Allergy and Infectious Diseases (R01AI052353, R37AI052353, R56AI052353, R01AI078908, U19AI095219, T32AI007306)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
  • Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
Keywords
lipid mediators, allergic diseases, asthma, allergic inflammation, prostaglandins, prostanoids, leukotrienes, zileuton, 5-lipoxygenase inhibitors, therapeutic target, diagnostic biomarkers
MeSH terms
Animals, Humans, Hypersensitivity, Lipids, Prostaglandin-Endoperoxide Synthases, Lipoxygenases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review